Alumis Inc (ALMS)

• Market cap: $3.17B
• 1 day: -3.01%
• 5 days: -1.82%
• 1 month: -7.6%
• 3 months: 129.84%
• 6 months: 492.54%
• Year to date: 183.71%
• 1 year: 467.41%
• 5 years: 91.13%
• 10 years: 91.13%
• Sector: Healthcare
• Industry: Biotechnology

About: Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

Employees: 233